ABSTRACT
Background and Aims: This study aims to describe the outcomes of evolving treatment regimens among COVID-19 confirmed severe and critical cases admitted at The Lung Center of the Philippines. Methods: A retrospective, cohort study conducted at The Lung Center of the Philippines from March 2020 to August 2020 that included 219 COVID-19 confirmed severe and critical patients. Results: Eleven out of 68 combinations of treatment regimens have significant difference in the proportion of survivors and non-survivors. Number of survivors is greatest for age group 50-59 (p= 0.106). Severe COVID-19 was associated with chronic kidney disease (p= 0.009). Most number of survivors is recorded for regimens with LCP standard of care 2 (antibiotic therapy, multivitamins + zinc, 02 therapy, IV fluid, and management of comorbidities + Anticoagulant + Dexamethasone) and high flow nasal cannula (HFNC). Combinations that included invasive ventilation showed an increased likelihood of death. Regression analysis showed that an increased Apache II score increased the likelihood of death and an increased PF ratio score lessened the probability of death. Median length of hospital stay is 11 days. Conclusions: Treatment regimens that included HFNC and LCP Standard of care 2 in combination with either interferon, tocilizumab, hemoperfusion, proning, or remdesivir decreases the likelihood of death. Invasive ventilation simultaneously given with any of the regimens increases the likelihood of death. Patients with higher Apache II scores and lower Pa02/Fi02 were non-survivors and in a more critical condition.